Get the Daily Brief
Latest Biotech News
Exciva raises €51M ($59M) Series B to push Alzheimer’s agitation candidate into Phase 2
German biotech Exciva closed a €51 million ($59 million) Series B to advance its lead program for agitation in Alzheimer’s disease into a mid‑stage clinical trial. The funding will support a Phase...
AI designs bacteriophages from scratch—scientists flag biosecurity implications
Researchers used AI models to design complete bacteriophage genomes de novo, demonstrating the ability to generate synthetic phages that can be synthesized and potentially deployed for therapeutic...
Monod Bio unveils AI‑designed ‘NovoBodies’—compact, customizable antibody mimics
Monod Bio, a spinout from David Baker’s lab, presented its AI platform for designing compact antibody mimics called NovoBodies—single‑chain, 27 kDa proteins engineered to reproduce antibody...
GSK buys Rapt for food-allergy IgE antibody: $2.2B deal
GSK agreed to acquire Bay Area biotech Rapt Therapeutics for $2.2 billion, taking rights to ozureprubart outside China and accelerating its entry into food-allergy therapeutics. The deal,...
Boston Scientific to buy Penumbra: $14.5B cardiovascular push
Boston Scientific announced a $14.5 billion cash-and-stock acquisition of Penumbra to expand its vascular and neurovascular portfolio. Under the terms, Penumbra shareholders may elect $374 per...
AstraZeneca pays up for C-CAR031 China rights — $630M pact
AstraZeneca agreed to acquire the remaining China rights to C‑CAR031 from AbelZeta Pharma for up to $630 million in upfront and milestone payments, giving the pharma firm full global control of a...
Engineered living glues target gut bleeding: autonomous IBD therapy
Two Nature Portfolio items (Nature Biotechnology and Nature) report engineered nonpathogenic E. coli strains that detect gastrointestinal bleeding and secrete an adhesive protein plus therapeutic...
UGA suppressor tRNA for AAV delivery unveiled — broad tropism move
Researchers published an engineered UGA‑suppressor tRNA designed to broaden AAV‑based therapeutic reach by enabling in vivo suppression of UGA stop codons, potentially allowing disease‑agnostic...
D3 Bio wins IND clearance for KRAS G12D inhibitor — first‑in‑human next
D3 Bio announced FDA IND clearance for D3S‑003, a KRAS G12D small‑molecule inhibitor, clearing the path to a first‑in‑human phase I trial in advanced solid tumors harboring the KRAS G12D mutation....
CAR‑T manufacturing boost: dextran nanoparticles and real‑time monitoring
Two manufacturing advances promise to address CAR‑T scalability: a dextran‑based nanoparticle platform shown to enhance CAR‑T production efficiency, and industry uptake of real‑time metabolic cell...
AI builds bacteriophages from scratch — breakthrough with biosecurity alarm
Researchers demonstrated AI models capable of designing complete bacteriophage genomes de novo, enabling synthetic generation of phages with tailored host ranges and payloads. The advance...
Exciva raises €51M ($59M) Series B to push Alzheimer’s agitation drug
Heidelberg‑based Exciva closed a €51 million ($59 million) Series B to advance its clinical candidate into phase 2 testing for agitation in Alzheimer’s disease. The financing will fund a mid‑stage...
FDA turmoil clouds 2025 approvals — agency in transition
Nature Biotechnology published an overview describing 2025 as a year of regulatory upheaval at the FDA: leadership changes, staff cuts and new policies impacted approval dynamics and the mix of...
Boston Scientific buys Penumbra: $14.5bn cardiovascular push
Boston Scientific agreed to acquire Penumbra in a $14.5 billion cash-and-stock transaction, expanding its portfolio into mechanical thrombectomy and neurovascular devices. The deal gives Boston...
AstraZeneca secures China rights to CAR-T C‑CAR031: $630M deal
AstraZeneca agreed to acquire the remaining China rights to AbelZeta’s armored CAR‑T candidate C‑CAR031 for up to $630 million, moving from a shared-rights arrangement to full global ownership of...
Exciva closes €51m Series B — advance Alzheimer’s agitation candidate
Heidelberg‑based Exciva raised €51 million ($59 million) in a Series B to advance a candidate targeting agitation in Alzheimer’s disease into Phase 2 testing. Company statements indicate proceeds...
FDA clears D3 Bio IND: KRAS G12D inhibitor D3S‑003 goes to clinic
D3 Bio received FDA IND clearance for D3S‑003, a KRAS G12D small‑molecule inhibitor, enabling first‑in‑human phase I studies in patients with advanced solid tumors harboring KRAS G12D mutations....
Engineered living glues: bacteria stick therapeutics to bleeding gut…
Two linked Nature/Nature Biotechnology reports describe engineered nonpathogenic E. coli programmed with a blood‑inducible circuit to secrete a barnacle‑derived adhesive (CP43K) and a therapeutic...
Therapeutic suppressor tRNA widens AAV delivery: Nature Biotech
A Nature Biotechnology report described an engineered UGA suppressor tRNA intended to expand AAV‑based protein delivery across disease contexts by enabling readthrough of UGA stop codons. The...
First circRNA protein‑replacement therapy targets liver fibrosis
Chinese researchers proposed and reported preclinical work on a circular RNA (circRNA) encoding human relaxin‑2 (cRLN2) as a protein‑replacement strategy for liver fibrosis. circRNAs offer...